A Prospective Clinical Study Evaluating the Harvesting of Micografts

Overview

ART (Autologous Regeneration of Tissue) is a revolutionary technology for harvesting skin without the drawbacks of conventional grafting. This innovative system allows the clinician to collect hundreds of microcolumns of full-thickness skin tissue and apply them directly to the wound site. It can all be done in an outpatient setting with minimized donor site concerns.

Full Title of Study: “A Prospective Clinical Study Evaluating the Efficiency of Full Thickness Micograft Harvesting in Healthy Volunteers and the Use of Full Thickness Micrografts in the Treatment of Patients With Chronic Wounds”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 13, 2021

Detailed Description

Millions of Americans suffer from acute and hard-to-heal chronic wounds. The National Institutes of Health estimates that 3% of the U.S. population over the age of 65 has an open wound. As the population ages in concert with an increased incidence of diabetes and obesity, the problem will intensify. A recent article suggests that the financial burden of wound care is approaching 100 billion dollars. Despite the gravity of the problem and the number of patients afflicted, open wounds can take weeks, months or even years to heal. The search for interventions that promote healing, reduce suffering and enhance quality of life continues as does the need to address the underlying issues that disrupt the wound healing process. Countless hours are spent treating chronic wounds (diabetic ulcers, venous ulcers, pressure injuries). Called the "silent epidemic," chronic wounds often result in infection, disability and sometimes amputation. Crafting a treatment plan that addresses the individual needs of each wound and each patient, hinges on managing the underlying issues that can disrupt healing and increase healthcare costs. Innovation in wound bed preparation and tissue regeneration bring new hope for these patients in the form of more effective wound closure, improved quality of life and reduced costs. Autologous skin grafting is the gold standard for covering areas of skin loss.4 However, traditional grafting is limited by accessibility issues and donor site complications-pain, risk of infection, scarring. ART (Autologous Regeneration of Tissue) is a revolutionary technology for harvesting skin without the drawbacks of conventional grafting. This innovative system allows the clinician to collect hundreds of microcolumns of full-thickness skin tissue and apply them directly to the wound site. It can all be done in an outpatient setting with minimized donor site concerns.

Interventions

  • Device: Autologous Regeneration of Tissue (ARTTM) system
    • The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.

Arms, Groups and Cohorts

  • Experimental: Evaluate the harvesting of micografts in healthy and patients with chronic wounds
    • The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.

Clinical Trial Outcome Measures

Primary Measures

  • To evaluate wound closure
    • Time Frame: 4 weeks
    • Evaluating Wound Closure with Surface area through measurments
  • Group A (Healthy Volunteers): The number of successful full thickness micrograft harvests from calf, thigh, and lower back as a percentage of the maximal possible grafts.
    • Time Frame: 4 weeks
    • Group A (Healthy Volunteers): The number of successful full thickness micrograft harvests from calf, thigh, and lower back as a percentage of the maximal possible grafts.
  • Group B (Chronic Wound patients): The number of wounds achieving a percentage area reduction (PAR) of 40% or greater in 4 weeks.
    • Time Frame: 4 weeks
    • Group B (Chronic Wound patients): The number of wounds achieving a percentage area reduction (PAR) of 40% or greater in 4 weeks.

Secondary Measures

  • Proportion of patients that achieve complete wound closure
    • Time Frame: 4 weeks
    • Proportion of patients that achieve complete wound closure by week 4. (Group B Only)
  • Time to initial wound closure within 4 weeks (Kaplan-Meier approach).
    • Time Frame: 4 weeks
    • Time to initial wound closure within 4 weeks (Kaplan-Meier approach). (Group B only)
  • Difference in pain between baseline
    • Time Frame: 4 weeks
    • Difference in pain between baseline and week 4 using a numeric scale 1-10. (Group B Only)
  • Number of Treatments used per patient.
    • Time Frame: 4 weeks
    • Number of Treatments used per patient. (Group B Only)
  • • Incidence of adverse events (calculated as total and mean number per patient).
    • Time Frame: 4 weeks
    • • Incidence of adverse events (calculated as total and mean number per patient). (Group B Only)

Participating in This Clinical Trial

Inclusion Criteria

Group A (Healthy Individuals) 1. 18 years or older. 2. Healthy participants without major diseases. Group B (Subjects with Chronic Wounds) 1. Participants presenting with chronic wound(s) present for a minimum of 4 weeks (eg. diabetic foot ulcers (DFU), venous leg ulcers (VLU), pressure ulcers (PrU), and other acceptable etiologies). 2. 18 years or older. Exclusion Criteria:

1. Subject on an investigational drug or therapeutic device within 30 days of the study visit. 2. Presence of a condition that PI considers will compromise the subject's ability to participate in the study. 3. Known allergy to any of the dressings or their components. 4. The subject has a history of excessive bleeding. 5. The subject has a history of keloid formation.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • SerenaGroup, Inc.
  • Collaborator
    • Medline Industries
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Thomas Serena, MD,FACS, Principal Investigator, SerenaGroup, Inc.
  • Overall Contact(s)
    • Thomas Serena, MD, FACS, 814- 688-4000, serena@serenagroups.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.